NCT04694963

Brief Summary

A prospective, multi-center, observational clinical trail. Aim to evaluate the real incidence of COPD pertussis and the impact of pertussis on subaute cough.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

26 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 24, 2020

Completed
8 days until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 5, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

January 5, 2021

Status Verified

December 1, 2020

Enrollment Period

6 months

First QC Date

December 24, 2020

Last Update Submit

January 4, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • Evaluation of the prevalence of pertussis among subacute cough

    According to the positive rate of bordetella pertussis nucleic acid, evaluate the prevalence of pertussis in subaute cough.

    Day 0 of each subject at the time of enrollment.

  • Evaluation of the correlation between pertussis and subacute cough

    Evaluate the correlation between pertussis infection and subacute cough by pertussis positive rate and clinical parameters.

    Day 0 of each subject at the time of enrollment.

Secondary Outcomes (3)

  • Evaluation of the seroprevalence of bordetella pertussis in subacute cough

    Day 0 of each subject at the time of enrollment.

  • Evaluation of the cut-off value for serological diagnosis of pertussis.

    Day 0 of each subject at the time of enrollment.

  • Evaluation of the subtype of bordetella pertussis.

    Day 0 of each subject at the time of enrollment.

Study Arms (1)

Subaute Cough

N=500

Procedure: Blood sampleProcedure: Data collectionProcedure: Throat swab

Interventions

Blood samplePROCEDURE

2 ml venous blood was collected and separated into serum.

Subaute Cough

1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination; 2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;

Subaute Cough
Throat swabPROCEDURE

Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue. Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth. Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time.

Subaute Cough

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with chronic cough in Shenzhen

You may qualify if:

  • The cough lasts 3 to 8 weeks and there is no obvious evidence of lung disease on chest X-ray.

You may not qualify if:

  • \. Major diseases except subaute cough; 2. Significant abnormality in laboratory examination; 3. Clinical diagnosis of lung cancer, bronchiectasis, pneumoconiosis or other simple restrictive ventilation dysfunction; 4. Patients with a history of asthma, allergic rhinitis, or a blood eosinophil count of 2600/mm3 (0.6x10\^9/L) within 4 weeks; 5. Currently suffering from active tuberculosis; 6. Patients with life-threatening pulmonary embolism, or al-antitrypsin deficiency, or cystic fibrosis; 7. Patients who have undergone lung resection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (26)

Fuyong people's Hospital of Baoan District, Shenzhen

Shenzhen, China

Location

General Hospital of Shenzhen University

Shenzhen, China

Location

Longhua Branch of Shenzhen People's Hospital

Shenzhen, China

Location

Nanshan District People's Hospital

Shenzhen, China

Location

Peking university shenzhen hospital

Shenzhen, China

Location

Shenzhen Bao'an District Central Hospital

Shenzhen, China

Location

Shenzhen Bao'an District People's Hospital

Shenzhen, China

Location

Shenzhen Hospital of Beijing University of traditional Chinese Medicine

Shenzhen, China

Location

Shenzhen Hospital of Southern Medical University

Shenzhen, China

Location

Shenzhen Hospital of the University of Hong Kong

Shenzhen, China

Location

Shenzhen Longgang District Central Hospital

Shenzhen, China

Location

Shenzhen Longgang District People's Hospital

Shenzhen, China

Location

Shenzhen Longgang District Second People's Hospital

Shenzhen, China

Location

Shenzhen Longgang District Third People's Hospital

Shenzhen, China

Location

Shenzhen Longhua District Central Hospital

Shenzhen, China

Location

Shenzhen Longhua District People's Hospital

Shenzhen, China

Location

Shenzhen Luohu District People's Hospital

Shenzhen, China

Location

Shenzhen People's Hospital

Shenzhen, China

Location

Shenzhen Pingshan District Hospital of traditional Chinese Medicine

Shenzhen, China

Location

Shenzhen Pingshan District People's Hospital

Shenzhen, China

Location

Shenzhen Qianhai Shekou Free Trade Zone Hospital

Shenzhen, China

Location

Shenzhen Second People's Hospital

Shenzhen, China

Location

Shenzhen TCM Hospital

Shenzhen, China

Location

Shenzhen Yantian District People's Hospital

Shenzhen, China

Location

South University of science and Technology Hospital

Shenzhen, China

Location

The eighth Affiliated Hospital of Sun Yat sen University

Shenzhen, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Throat swab, Peripheral blood

MeSH Terms

Conditions

Whooping CoughChronic Cough

Interventions

Blood Specimen CollectionData Collection

Condition Hierarchy (Ancestors)

Bordetella InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsRespiratory Tract InfectionsRespiratory Tract DiseasesCoughRespiration DisordersSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesEpidemiologic MethodsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Lingwei Wang

    Shenzhen People's Hospital

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 24, 2020

First Posted

January 5, 2021

Study Start

January 1, 2021

Primary Completion

June 30, 2021

Study Completion

December 31, 2021

Last Updated

January 5, 2021

Record last verified: 2020-12

Data Sharing

IPD Sharing
Will not share

Locations